IQVIA Holdings: Strong Financial Performance and Promising Outlook Amidst Market Challenges

Michael Ryskin, an analyst from Bank of America Securities, reiterated the Buy rating on IQVIA Holdings (IQV – Research Report). The associated price target remains the same with $190.00.

Michael Ryskin’s rating is based on IQVIA Holdings’ strong financial performance and promising future outlook. The company’s first-quarter sales and adjusted earnings per share exceeded expectations, with a favorable foreign exchange impact leading to an increase in the full-year 2025 sales guidance. Additionally, the Technology & Analytics Solutions (TAS) segment showed signs of recovery and strength, particularly in the Real-World Evidence business, which is expected to benefit from potential regulatory changes in clinical trials.
Despite challenges in the biotech sector and uncertainties due to policy changes, IQVIA’s management remains optimistic about the future. The company has demonstrated resilience and adaptability in a dynamic macroeconomic environment, maintaining its competitive position. The reaffirmation of the Buy rating and a price objective of $190 reflects confidence in IQVIA’s long-term fundamentals and its ability to navigate complex market conditions.

In another report released yesterday, Evercore ISI also maintained a Buy rating on the stock with a $165.00 price target.